(3R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物 - 呋喃类木脂素
• 英文名称: (3R)-4-[(3,4-dimethoxyphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one
• 化学式: C₂₁H₂₄O₆
• 分子量: 372.4
• InChiKey: NQWVSMVXKMHKTF-OEMAIJDKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Method of preparing ATG's analogue, and the application of ATG and it's analogue
  申请人：Longhua Hospital Shanghai University of Traditional Chinese Medicine

  公开号：US20170313667A1

  公开（公告）日：2017-11-02

  The present invention provides the use of ATG in the preparation of a reagent for adjusting the activity of PP2A; and the use of ATG in increasing the activity of PP2A in 293T cells. The present invention also provides the use of the arctigenin in the preparation of the medicine for reducing the proteinuria of the diabetic mice. The present invention also provides the use of the arctigenin in the preparation of the reagent for inhibiting the expression of the NOX4 gene. The present invention also provides analogues of arctigenin and application thereof. The present invention provides a novel use of ATG for modulating PP2A activity, and ATG can also significantly reduce proteinuria in diabetic mice. At the same time, arctigenin could significantly inhibit the expression of NOX4 in STZ-eNOS −/− mice glomeruli. The ATG analogues of the present invention are more effective than the native ATG.

  本发明提供了在制备用于调节PP2A活性的试剂时使用ATG的方法；以及在增加293T细胞中PP2A活性时使用ATG的方法。本发明还提供了在制备用于降低糖尿病小鼠蛋白尿的药物中使用牛蒡苷的方法。本发明还提供了在制备抑制NOX4基因表达的试剂中使用牛蒡苷的方法。本发明还提供了牛蒡苷的类似物及其应用。本发明提供了ATG用于调节PP2A活性的新用途，ATG还可以显著减少糖尿病小鼠的蛋白尿。同时，牛蒡苷可以显著抑制STZ-eNOS−/−小鼠的肾小球中NOX4的表达。本发明的ATG类似物比原生ATG更有效。
• Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
  申请人：Maziasz Timothy

  公开号：US20050026902A1

  公开（公告）日：2005-02-03

  The present invention provides compositions and methods for the treatment of human immunodeficiency virus (HIV) infection as well as HIV associated diseases and related disorders. More particularly, the invention provides a combination therapy for the treatment of HIV infection as well as HIV associated diseases and related disorders comprising the administration to a subject of an anti-human immunodeficiency virus agent in combination with a cyclooxygenase-2 selective inhibitor or an isomer or a pharmaceutically acceptable salt, ester, or prodrug thereof.

  本发明提供了治疗人类免疫缺陷病毒（HIV）感染以及HIV相关疾病和相关紊乱的组合物和方法。更具体地说，本发明提供了一种治疗HIV感染以及HIV相关疾病和相关紊乱的组合疗法，包括向受试者施用抗人类免疫缺陷病毒制剂与环氧化酶-2选择性抑制剂或其异构体或其药学上可接受的盐、酯或原药组合。
• US9994533B2
  申请人：——

  公开号：US9994533B2

  公开（公告）日：2018-06-12